Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer

Pancreas. 2010 Mar;39(2):253-5. doi: 10.1097/MPA.0b013e3181bdc6b8.
No abstract available

Publication types

  • Letter
  • Meta-Analysis

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antimetabolites, Antineoplastic / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Disease-Free Survival
  • ErbB Receptors / antagonists & inhibitors
  • Evidence-Based Medicine
  • Gemcitabine
  • Humans
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / mortality
  • Protein Kinase Inhibitors / administration & dosage
  • Randomized Controlled Trials as Topic
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Protein Kinase Inhibitors
  • Deoxycytidine
  • EGFR protein, human
  • ErbB Receptors
  • Receptors, Vascular Endothelial Growth Factor
  • Gemcitabine